Back

UBS keeps Buy on Perspective Therapeutics with $8 target; BTIG holds Integra

Verifying
  • UBS maintained a Buy rating on Perspective Therapeutics with an $8.00 price target.
  • Perspective Therapeutics closed at $2.76, while its consensus target was $12.30.
  • BTIG maintained Hold on Integra Lifesciences, whose consensus target was $18.33.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.